April 2026
Serotonin
What April 2026's 5 new studies found, synthesized from the papers below. All Serotonin research →
The synthesis
Synthesized from 5 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Serotonin, 5-HT, serotonergic, 5-HT2A receptor, then ranked by relevance.
Research on serotonin in April 2026 focused on developing novel serotonergic compounds and understanding psychedelic mechanisms. Studies introduced 2-halogenated tryptamines as potential next-generation therapeutics with reduced psychoactivity and cardiotoxicity, and identified a conserved glucocorticoid-responsive gene signature induced by psilocybin across multiple brain regions in rats. However, evidence for clinical efficacy in conditions like Alzheimer's disease remains preclinical and hypothesis-generating, and the field is still limited by small sample sizes and lack of human trials.
Confidence in the evidence
Low-Moderate- Only five studies were provided, with two being preclinical animal studies and one a review, limiting generalizability.
- The largest experimental study had a sample size of 24 rats, which is small for drawing broad conclusions.
- One study is a review and another is a hypothesis-generating model, both lacking original empirical data.
- No human clinical trials were included; all evidence is preclinical or theoretical.
- The studies are consistent in direction but cover diverse aspects of serotonin research, preventing a unified conclusion.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Novel Indoline Derivatives Serotonergic Psychedelic Agents as 5‑HT2A Agonists for Treating Psychosis, Mental Illness and CNS Disorders. 2026 | theoretical | Supports | This study proposes novel indoline derivatives as 5-HT2A agonists for treating psychosis and CNS disorders. | |
| Serotonergic Polypharmacology of 2-Halogenated Tryptamines. 2026 | preclinical | Supports | 2-halogenated tryptamines showed reduced 5-HT2A/5-HT2B activity, preserved 5-HT6 agonism, and improved stress-induced affective measures in mice without inducing psychedelic effects. | |
| Psilocybin elicits a conserved glucocorticoid-responsive gene signature across five 5-HT2A receptor-rich brain regions in rat. 2026 | preclinical | 24 | Supports | Psilocybin induced a conserved glucocorticoid-responsive gene signature (e.g., Nfkbia, Sgk1 upregulation) across five 5-HT2A receptor-rich brain regions in rats. |
| Dorsal Raphe Revisited: A Systems Neuroscience Lens on Psychedelic Drug Action 2026 | review | Unclear | This review traces the history of LSD research on the dorsal raphe, concluding that early hypotheses about serotonergic neurons driving hallucinogenic effects have shifted toward a systems neuroscience perspective. | |
| Hallucinogenic Therapy in Alzheimer's Disease targeting Mitochondria-Associated Membranes. 2026 | theoretical | Supports | This hypothesis-generating model suggests that classic hallucinogens may restore mitochondrial integrity in Alzheimer's disease via 5-HT2A and sigma-1 receptors, but evidence remains preclinical. |
This study proposes novel indoline derivatives as 5-HT2A agonists for treating psychosis and CNS disorders.
theoretical
2-halogenated tryptamines showed reduced 5-HT2A/5-HT2B activity, preserved 5-HT6 agonism, and improved stress-induced affective measures in mice without inducing psychedelic effects.
preclinical
Psilocybin induced a conserved glucocorticoid-responsive gene signature (e.g., Nfkbia, Sgk1 upregulation) across five 5-HT2A receptor-rich brain regions in rats.
preclinical Sample size: 24
This review traces the history of LSD research on the dorsal raphe, concluding that early hypotheses about serotonergic neurons driving hallucinogenic effects have shifted toward a systems neuroscience perspective.
review
This hypothesis-generating model suggests that classic hallucinogens may restore mitochondrial integrity in Alzheimer's disease via 5-HT2A and sigma-1 receptors, but evidence remains preclinical.
theoretical
Points of agreement
- All studies implicate the 5-HT2A receptor as a key target for serotonergic psychedelics and related compounds.
- Preclinical evidence consistently supports the therapeutic potential of serotonergic compounds for psychiatric and neurodegenerative conditions.
- The studies agree that reducing 5-HT2A activity can mitigate psychoactive effects while preserving therapeutic benefits.
Conflicts
- No direct conflicts are reported; however, the review (article 28034) notes that early hypotheses about serotonergic neurons driving hallucinogenic effects have been revised, contrasting with earlier interpretations.
Gaps
- No human clinical trials are included; all evidence is preclinical or theoretical.
- Durability of effects and long-term safety are not addressed.
- The studies lack diverse populations and do not examine dose-response relationships in humans.
- The translational feasibility and neuropsychiatric safety of these compounds remain unstudied in clinical settings.